-
Go 6983: Reproducible PKC Assay Workflows
2026-08-20
This scenario-driven guide explains how Go 6983 (pan-PKC inhibitor), SKU A8343, can improve experimental planning for viability, proliferation, cytotoxicity, cancer progression, and EMT studies. It covers isoform potency, DMSO handling, controls, interpretation, and practical vendor-selection criteria for PKC signaling pathway research.
-
4-Phenylbutyric Acid in ER Stress Workflows
2026-08-19
Use 4-Phenylbutyric acid as a controllable chemical-chaperone intervention to separate endoplasmic reticulum stress from ferroptotic injury in cell-based assays. The workflow below adapts a PFOS-treated HK-2 model into a practical design for ER stress alleviation, mechanistic rescue testing, and assay troubleshooting.
-
Patient-Derived Gastric Cancer Assembloids
2026-08-19
Shapira-Netanelov and colleagues developed a patient-derived gastric cancer assembloid that combines matched tumor organoids with tumor-derived stromal subpopulations. The model reveals how stromal context reshapes gene expression and drug sensitivity, creating a more physiologically informative platform for studying resistance and personalized treatment strategies.
-
Cyclosporin A (B1922): Practical Protocol Guide
2026-08-18
Cyclosporin A (SKU B1922) provides a defined cyclophilin-inhibiting reagent for cell-based immunosuppression, apoptosis modulation, and mitochondrial studies. This guide distinguishes product-dossier values from workflow recommendations and explains where the compound should not be interpreted as a validated clinical or universal in vivo treatment.
-
Sulfaphenazole-Derived Sulfonamides for TB
2026-08-18
Chen and colleagues optimized sulfaphenazole-derived sulfonamides to retain antimycobacterial activity while reducing CYP 2C9 inhibition, a liability associated with drug–drug interaction risk. Compound 10d emerged as the leading example, combining an MIC of 5.69 μg/mL against Mycobacterium tuberculosis with CYP 2C9 inhibition weaker than 10 μM in the reported assay.
-
HNF4A-AS1, Lipid Metabolism, and Sorafenib Resistance
2026-08-17
A 2024 Theranostics study identifies the liver-enriched lncRNA HNF4A-AS1 as a suppressor of sorafenib resistance in hepatocellular carcinoma. Its mechanistic analysis links HNF4A-AS1 to METTL3-dependent m6A modification, YTHDF3-mediated DECR1 mRNA degradation, PUFA depletion, and ferroptosis sensitivity.
-
Omeprazole A2845: Practical Research Workflow
2026-08-17
Omeprazole A2845 provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research and related antiulcer assay development. It is intended for in vitro or ex vivo scientific workflows, not for diagnosis, treatment, or direct clinical use.
-
Omeprazole A2845: H+,K+-ATPase Research
2026-08-16
Omeprazole (SKU A2845) provides a research-grade H+,K+-ATPase inhibitor for controlled studies of gastric acid secretion, proton-pump inhibition, and related antiulcer workflows. Its dossier defines assay-specific potency, DMSO solubility, storage, and handling requirements, but the material is not intended for diagnostic, clinical, or therapeutic use.
-
DMG-PEG2000-NH2 for LNP Workflow Optimization
2026-08-15
DMG-PEG2000-NH2 combines a lipid-compatible scaffold with a primary amine for controlled conjugation to carboxyl-containing biomolecules. This guide translates its chemistry into practical liposome, lipid nanoparticle, and siRNA encapsulation workflows while using the sulfaphenazole optimization study as a model for better assay design.
-
O-GlcNAc–HUWE1–TfR1 Axis in Preeclampsia
2026-08-14
This study identifies an O-GlcNAc–HUWE1–TfR1 pathway that links trophoblast iron handling, ferroptosis, and syncytialization defects in preeclampsia. Its mechanistic and in vivo findings suggest that stabilizing O-GlcNAcylated HUWE1 may reduce TfR1-dependent iron uptake and improve pregnancy-associated pathology, while also defining important limits for translation.
-
CCR5-Positive EVs in Rheumatoid Arthritis
2026-08-14
The reference study identifies CCR5-bearing extracellular vesicles released by rheumatoid arthritis synovial fibroblasts as mediators of cartilage destruction, bone erosion, and NF-κB activation. By comparing native, CCR5-depleted, and Maraviroc-loaded vesicles in human cell systems and adjuvant-induced arthritis rats, it provides a mechanistic rationale for targeting EV-associated CCR5 rather than studying the receptor only at the cell surface.
-
XXLP and the NOX2/ROS/Mitochondria/NLRP3 Axis
2026-08-13
A 2026 study links Xu Chunfu’s Modified Xianglian Pill with suppression of the NOX2/ROS/mitochondria/NLRP3 inflammatory axis in DSS-induced colitis. Its integrated chemical, proteomic, cellular, ultrastructural, and microbiome analyses provide a mechanistic framework for interpreting this traditional formulation while highlighting the need for direct metabolic and translational validation.
-
DiI (DiIC18(3)) Plasma Membrane Probe
2026-08-13
DiI (DiIC18(3)) is a lipophilic orange fluorescent dye for labeling plasma membranes in live or fixed cells and tissues, with applications including neuronal tracing, migration, adhesion, and membrane-associated labeling. It should not be dissolved directly in water or used as an intracellular organelle marker, and detergent permeabilization requires validation because it can disrupt membrane-localized signal.
-
Measuring Drug Response Beyond Cell Viability
2026-08-12
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these measures capture different combinations of growth inhibition and cell killing. The findings support paired, time-aware in vitro assays that can improve interpretation of anti-cancer drug responses in cancer research.
-
SJ572946 Activates BAK to Initiate Apoptosis
2026-08-12
The reference study identifies SJ572946 as a fragment-derived small molecule that binds the BAK activation groove and selectively promotes BAK-mediated mitochondrial membrane permeabilization over BAX activation. Its activity in engineered tumor cells and its cooperation with BID, apoptotic inducers, and BH3 mimetics establish SJ572946 as a proof-of-concept tool for dissecting direct BAK activation.